Cognitive deficit in schizophrenia and its neurochemical basis

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Cognitive impairment is a central feature of schizophrenia and has been correlated with negative symptoms and impaired social functioning. There is a growing body of data suggesting that the so-called atypical antipsychotic drugs (e.g. clozapine, risperidone, and olanzapine) are better at enhancing cognitive function than traditional neuroleptics. Preclinical studies of information processing using a pre-pulse inhibition model show that the mechanism of action of both olanzapine and clozapine for cognitive enhancement may involve glutamatergic/N-methyl-D-aspartate (NMDA) antagonism. Using positron emission tomography, we have described the metabolic and neurochemical correlates of cognitive impairment induced by glutamatergic/NMDA antagonism. A better understanding of the underlying causes of cognitive impairment may contribute to elucidating the pathophysiology of schizophrenia and the development of more efficacious treatments for this disorder.

Original languageEnglish (US)
Pages (from-to)16-18
Number of pages3
JournalBritish Journal of Psychiatry
Volume174
Issue numberFEB. SUPPL. 37
StatePublished - 1999

Fingerprint

olanzapine
Schizophrenia
Clozapine
N-Methylaspartate
Antipsychotic Agents
Risperidone
Automatic Data Processing
Positron-Emission Tomography
Cognition
Cognitive Dysfunction

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Cognitive deficit in schizophrenia and its neurochemical basis. / Breier, Alan.

In: British Journal of Psychiatry, Vol. 174, No. FEB. SUPPL. 37, 1999, p. 16-18.

Research output: Contribution to journalArticle

@article{95d5dd52a9f748c9900498e6f31145e6,
title = "Cognitive deficit in schizophrenia and its neurochemical basis",
abstract = "Cognitive impairment is a central feature of schizophrenia and has been correlated with negative symptoms and impaired social functioning. There is a growing body of data suggesting that the so-called atypical antipsychotic drugs (e.g. clozapine, risperidone, and olanzapine) are better at enhancing cognitive function than traditional neuroleptics. Preclinical studies of information processing using a pre-pulse inhibition model show that the mechanism of action of both olanzapine and clozapine for cognitive enhancement may involve glutamatergic/N-methyl-D-aspartate (NMDA) antagonism. Using positron emission tomography, we have described the metabolic and neurochemical correlates of cognitive impairment induced by glutamatergic/NMDA antagonism. A better understanding of the underlying causes of cognitive impairment may contribute to elucidating the pathophysiology of schizophrenia and the development of more efficacious treatments for this disorder.",
author = "Alan Breier",
year = "1999",
language = "English (US)",
volume = "174",
pages = "16--18",
journal = "British Journal of Psychiatry",
issn = "0007-1250",
publisher = "Royal College of Psychiatrists",
number = "FEB. SUPPL. 37",

}

TY - JOUR

T1 - Cognitive deficit in schizophrenia and its neurochemical basis

AU - Breier, Alan

PY - 1999

Y1 - 1999

N2 - Cognitive impairment is a central feature of schizophrenia and has been correlated with negative symptoms and impaired social functioning. There is a growing body of data suggesting that the so-called atypical antipsychotic drugs (e.g. clozapine, risperidone, and olanzapine) are better at enhancing cognitive function than traditional neuroleptics. Preclinical studies of information processing using a pre-pulse inhibition model show that the mechanism of action of both olanzapine and clozapine for cognitive enhancement may involve glutamatergic/N-methyl-D-aspartate (NMDA) antagonism. Using positron emission tomography, we have described the metabolic and neurochemical correlates of cognitive impairment induced by glutamatergic/NMDA antagonism. A better understanding of the underlying causes of cognitive impairment may contribute to elucidating the pathophysiology of schizophrenia and the development of more efficacious treatments for this disorder.

AB - Cognitive impairment is a central feature of schizophrenia and has been correlated with negative symptoms and impaired social functioning. There is a growing body of data suggesting that the so-called atypical antipsychotic drugs (e.g. clozapine, risperidone, and olanzapine) are better at enhancing cognitive function than traditional neuroleptics. Preclinical studies of information processing using a pre-pulse inhibition model show that the mechanism of action of both olanzapine and clozapine for cognitive enhancement may involve glutamatergic/N-methyl-D-aspartate (NMDA) antagonism. Using positron emission tomography, we have described the metabolic and neurochemical correlates of cognitive impairment induced by glutamatergic/NMDA antagonism. A better understanding of the underlying causes of cognitive impairment may contribute to elucidating the pathophysiology of schizophrenia and the development of more efficacious treatments for this disorder.

UR - http://www.scopus.com/inward/record.url?scp=0032988186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032988186&partnerID=8YFLogxK

M3 - Article

VL - 174

SP - 16

EP - 18

JO - British Journal of Psychiatry

JF - British Journal of Psychiatry

SN - 0007-1250

IS - FEB. SUPPL. 37

ER -